Unit
Brustzentrum St.Gallen
BZ · Dept. IV
pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials
Reinisch M, Nekljudova V V, Untch M, Lederer B, Rhiem K, Schneeweiss A, Kümmel S, Jackisch C, Hanusch C, Denkert C, Blohmer J, von Minckwitz G, Huober J, Loibl S. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Breast 2017; 32:73-78.
Jan 5, 2017pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials
Jan 5, 2017Breast 2017; 32:73-78
Reinisch Mattea, Nekljudova V Valentina, Untch Michael, Lederer Bianca, Rhiem Kerstin, Schneeweiss Andreas, Kümmel Sherko, Jackisch Christian, Hanusch Claus, Denkert Carsten, Blohmer Jens-Uwe, von Minckwitz Gunter, Huober Jens, Loibl Sibylle
Slit2/Robo4 Signaling: Potential Role of a VEGF-Antagonist Pathway to Regulate Luteal Permeability
Bekes I, Haunerdinger V, Sauter R, Holzheu I, Janni W, Wöckel A, Wulff C. Slit2/Robo4 Signaling: Potential Role of a VEGF-Antagonist Pathway to Regulate Luteal Permeability. Geburtshilfe Frauenheilkd 2017; 77:73-80.
Jan 1, 2017Slit2/Robo4 Signaling: Potential Role of a VEGF-Antagonist Pathway to Regulate Luteal Permeability
Jan 1, 2017Geburtshilfe Frauenheilkd 2017; 77:73-80
Bekes Inga, Haunerdinger V, Sauter R, Holzheu I, Janni W, Wöckel A, Wulff C
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2017; 28:2899.
Jan 1, 2017Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Jan 1, 2017Ann Oncol 2017; 28:2899
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel.
Rostetter C, Rordorf T, Essig H, Zweifel D, Schumann P, Rücker M, Bredell M. Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel. Swiss Dent J 2017; 127:520-521.
Jan 1, 2017Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel.
Jan 1, 2017Swiss Dent J 2017; 127:520-521
Rostetter Claudio, Rordorf Tamara, Essig Harald, Zweifel Daniel F, Schumann Paul, Rücker Martin, Bredell Marius
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller T, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Ann Oncol 2016
Dec 19, 2016Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Dec 19, 2016Ann Oncol 2016
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann Beat, Moos R von, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller Thomas, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess Dagmar, Mamot C
Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue.
Ernst J, Ikenberg K, Apel B, Schumann D, Huber G, Studer G, Rordorf T, Riesterer O, Rössle M, Korol D, Bredell M. Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. Oncotarget 2016; 7:76151-76158.
Nov 15, 2016Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue.
Nov 15, 2016Oncotarget 2016; 7:76151-76158
Ernst Jutta, Ikenberg Kristian, Apel Barbara, Schumann Desiree M, Huber Gerhard, Studer Gabriela, Rordorf Tamara, Riesterer Oliver, Rössle Matthias, Korol Dimitri, Bredell Marius
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC cancer 2016; 16:780.
Oct 10, 2016SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Oct 10, 2016BMC cancer 2016; 16:780
Rochlitz Christoph, Rordorf Tamara, Rauch Daniel, Müller Andreas, Ruhstaller Thomas, Vetter Marcus, Trojan Andreas, Hasler-Strub Ursula, Cathomas Richard, Winterhalder Ralph, Borner Markus, Bärtschi Daniela, Bigler Martin, von Moos Roger, Bernhard Jürg, Matter-Walstra Klazien, Wicki Andreas, Zaman Khalil, Anchisi Sandro, Küng Marc, Na Kyung-Jae
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese W, Kopit J, Shaw J, Gillison M. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375:1856-1867.
Oct 8, 2016Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Oct 8, 2016N Engl J Med 2016; 375:1856-1867
Ferris Robert L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Monga Manish, Lynch Mark, Geese William J, Kopit Justin, Shaw James W, Gillison Maura L
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
Pruneri G, Regan M, Gelber R, Munzone E, Cancello G, Price K, Kammler R, Goldhirsch A, Gianni L, Ruhstaller T, Láng I, Criscitiello C, Curigliano G, Viale G, Vingiani A, Gray K, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat 2016; 158:323-31.
Jul 2, 2016Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
Jul 2, 2016Breast Cancer Res Treat 2016; 158:323-31
Pruneri Giancarlo, Regan Meredith M, Gelber Richard D, Munzone Elisabetta, Cancello Giuseppe, Price Karen N, Kammler Roswitha, Goldhirsch Aron, Gianni Lorenzo, Ruhstaller Thomas, Láng István, Criscitiello Carmen, Curigliano Giuseppe, Viale Giuseppe, Vingiani Andrea, Gray Kathryn P, Colleoni Marco
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Colleoni M, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber R, Regan M, Coates A, Price K, Viale G, Kralidis E, Tondini C, Gray K, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E, Gomez H, Linderholm B, Puglisi F, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol 2016
Jun 20, 2016Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Jun 20, 2016J Clin Oncol 2016
Colleoni Marco, Eniu Alexandru, Cagossi Katia, Rauch Daniel, Chirgwin Jacquie, Gelber Richard D, Regan Meredith M, Coates Alan S, Price Karen N, Viale Giuseppe, Kralidis Elena, Tondini Carlo, Gray Kathryn P, Gelber Shari, Láng István, Thürlimann Beat, Gianni Lorenzo, Abdi Ehtesham A, Gomez Henry L, Linderholm Barbro K, Puglisi Fabio, Goldhirsch Aron
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
von Minckwitz G, Jackisch C, Kümmel S, Fasching P, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober J, Gerber B, Zahm D, Hilfrich J, Costa S, Dubsky P, Blohmer J, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). Eur J Cancer 2016; 64:12-21.
Jun 17, 2016Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
Jun 17, 2016Eur J Cancer 2016; 64:12-21
von Minckwitz G, Jackisch C, Kümmel S, Fasching P A, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober Jens, Gerber B, Zahm D M, Hilfrich J, Costa S D, Dubsky P, Blohmer J U, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators
IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80.
Brown M, Glanzmann C, Huber G, Bredell M, Rordorf T, Studer G. IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80. Strahlenther Onkol 2016; 192:526-36.
Jun 15, 2016IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80.
Jun 15, 2016Strahlenther Onkol 2016; 192:526-36
Brown Michelle L, Glanzmann Christoph, Huber Gerhard, Bredell Marius, Rordorf Tamara, Studer Gabriela
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes K. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer Res Treat 2016; 158:51-7.
Jun 8, 2016Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
Jun 8, 2016Breast Cancer Res Treat 2016; 158:51-7
Matter-Walstra K, Ruhstaller Thomas, Klingbiel D, Schwenkglenks M, Dedes K J
Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost
Ebner F, Janni W, Bekes I, Lato K, Fink V, Wiegel T, Friedl T, Bottke D, Schramm A, De Gregorio N. Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost. Arch Gynecol Obstet 2016; 294:861-6.
Jun 2, 2016Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost
Jun 2, 2016Arch Gynecol Obstet 2016; 294:861-6
Ebner Florian, Janni Wolfgang, Bekes Inga, Lato Kristian, Fink Visnja, Wiegel Thomas, Friedl Thomas Wp, Bottke Dirk, Schramm Amelie, De Gregorio Nikolaus
Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis
Warschkow R, Gueller U, Tarantino I, Cerny T, Schmied B, Thürlimann B, Jörger M. Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis. Ann Surg 2016; 263:1188-98.
Jun 1, 2016Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis
Jun 1, 2016Ann Surg 2016; 263:1188-98
Warschkow Rene, Gueller Ulrich, Tarantino Ignazio, Cerny Thomas, Schmied Bruno, Thürlimann Beat, Jörger Markus
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Chirgwin J, Colleoni M, Láng I, Neven P, Forbes J, Rabaglio M, Smith I, Goldhirsch A, Gelber R, Debled M, Ejlertsen B, Price K, Coates A, Giobbie-Hurder A, Thürlimann B. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol 2016; 34:2452-9.
May 23, 2016Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
May 23, 2016J Clin Oncol 2016; 34:2452-9
Chirgwin Jacquie H, Colleoni Marco, Láng István, Neven Patrick, Forbes John F, Rabaglio Manuela, Smith Ian, Goldhirsch Aron, Gelber Richard D, Debled Marc, Ejlertsen Bent, Price Karen N, Coates Alan S, Giobbie-Hurder Anita, Thürlimann Beat
A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction
Warschkow R, Cerny T, Schmied B, Gueller U, Thürlimann B, Jörger M. A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction. Br J Cancer 2016; 115:80-4.
May 17, 2016A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction
May 17, 2016Br J Cancer 2016; 115:80-4
Warschkow Rene, Cerny Thomas, Schmied Bruno, Gueller Ulrich, Thürlimann Beat, Jörger Markus
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Schwentner L, Janni W, Kiechle M, Härtl K, Weissenbacher T, Friedl T, Huober J, Scholz C, Wischnik A, Forstbauer H, Rack B, Eichler M, Singer S, Harbeck N, Fink V. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast 2016; 27:69-77.
Apr 4, 2016Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Apr 4, 2016Breast 2016; 27:69-77
Schwentner Lukas, Janni Wolfgang, Kiechle Marion, Härtl Kristin, Weissenbacher Tobias, Friedl Thomas W P, Huober Jens, Scholz Christoph, Wischnik Arthur, Forstbauer Helmut, Rack Brigitte, Eichler Martin, Singer Susanne, Harbeck Nadia, Fink Visnja
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
Janni W, Friedl T, Zwingers T, Huober J, Scholz C, Annecke K, Wischnik A, Jueckstock J, Augustin D, Rack B, Harbeck N, Kiechle M. Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. Br J Cancer 2016; 114:863-71.
Mar 31, 2016Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
Mar 31, 2016Br J Cancer 2016; 114:863-71
Janni W, Friedl T W P, Zwingers T, Huober Jens, Scholz C, Annecke K, Wischnik A, Jueckstock J, Augustin D, Rack B, Harbeck N, Kiechle M
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Ribi K, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates A, Goldhirsch A, Price K, Gelber R, Regan M, Neven P, Perelló A, Kerbrat P, Luo W, Bernhard J, Francis P, Burstein H, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Fleming G. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 2016; 34:1601-10.
Mar 28, 2016Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Mar 28, 2016J Clin Oncol 2016; 34:1601-10
Ribi Karin, Torres Roberto, Lombardi Davide, Puglisi Fabio, Karlsson Per, Ruhstaller Thomas, Colleoni Marco, Coates Alan S, Goldhirsch Aron, Price Karen N, Gelber Richard D, Regan Meredith M, Neven Patrick, Perelló Antonia, Kerbrat Pierre, Luo Weixiu, Bernhard Jürg, Francis Prudence A, Burstein Harold J, Ciruelos Eva, Bellet Meritxell, Pavesi Lorenzo, Lluch Ana, Visini Marilena, Parmar Vani, Tondini Carlo, Fleming Gini F